	PATENT APPLICATION
	DOCKET NO.: 2825-2023-00
7	1///

I	N THE UNITED STATES	S PATENT AND TRADEN	MARK OFFICE	TP
Applicants:	Todd R. Golub, Eric S	. Lander, Scott Pomeroy ar	nd Pablo Tamayo	FEB 2 '
Application No.:	10/066,305	Group Art Unit:	1642	
Filed:	January 31, 2002	Examiner:	K. Canella	WY & TP
Confirmation No.:	2026	•		, e
Title:	BRAIN TUMOR DIA	GNOSIS AND OUTCOM	E PREDICTION	
•	I hereby certify that this co States Postal Service with su addressed to Assistant Comm 22202 on 02/14/03 Date Car Typed or print	RTIFICATE OF MAILING brrespondence is being deposited with the afficient postage as First Class Mail in architecture for Patents, P.O. Box 2327, Arthogodology and the signature signature to 1 M. Bowerman ted name of person signing certificate RMATION DISCLOSURE STATES.	n envelope ington, VA	TAP TO
Assistant Commissi P.O. Box 2327 Arlington, VA 2220		i 02/21/	2003 NMOHAMM1 00000091 10	<b>ስ</b> ሰደ ር ንሎ!
Sir:		, 01 FC:		180
This Information I	Disclosure Statement is sub	omitted:		
	FR 1.129(a), or bmission after Final Rejection)			
(Within any one stage in an inter		onths of filing national application (othe		
.[X] under 37 C	CFR 1.97(c) together with e	either:		
. ,		97(e), as checked below, or		
	180.00 fee under 37 CFR 1 FR 1.97(b) time period, but before final	1.17(p), or action or notice of allowance, whicheve	r occurs first)	
[ ] under 37 C	CFR 1.97(d) together with:			
[ ] a S	tatement under 37 CFR 1.9	97(e), as checked below, an	d	

[ ] under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

a \$180.00 fee under 37 CFR 1.17(p), or

## Statement Under 37 CFR 1.97(e)

[X]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or						
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.						
Stater	nent Un	der 37 (	(Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000				
[X]	comm was n	unication of receiver	information contained in the Information Disclosure Statement was cited in a son from a foreign patent office in a counterpart application and this communication ared by any individual designated in § 1.56(c) more than thirty days prior to the aformation Disclosure Statement.				
[X]	Enclosed herewith is form PTO-1449:						
	[X]	Copies	s of the cited references are enclosed.				
	[ ]	Applic	s of cited references are enclosed except those entered in prior application, U.S. eation No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier ation contains copies of the cited references.]				
	[X]	The list	sted references were cited in the enclosed International Search Report in a expart foreign application.				
	[ ]	oncise explanation" requirement (non-English references) for reference(s) [ 37 CFR 1.98(a)(3) is satisfied by:					
		[ ]	the explanation provided on the attached sheet.				
		[ ]	the explanation provided in the Specification.				
	•	[ ]	submission of the enclosed International Search Report.				
•		[ ]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.				
		[ ]	the enclosed English language abstract.				

[ ]	Applio	cant requests that the following r	non-published pending applic	cations be considered:			
Examiner's Initials							
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]			
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]			
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]			
		Examiner	Date	_			
				•			
	[ ]	A copy of each above-cited app	plication, including the curre	nt claims, is enclosed.			
	[ ]	A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.					
		r is requested to return a copy of re considered with the next offic		plications indicating which			
It is re	quested	that the information disclosed h	nerein be made of record in the	nis application.			
Metho	d of pa	yment:					
[ , ]	A checaccom	ck for the fee noted above is enc panying Reply. A copy of this S	losed, or the fee has been inc Statement is enclosed.	luded in the check with the			
[]	Please	e charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is sed.					
[X]	Please	se charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.					
		F	Respectfully submitted,				
•	•	F	HAMILTON, BROOK, SMI	ΓΗ & REYNOLDS, P.C.			
		I F 7	By Lisa M. Treannie Registration No.: 41,368 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	Teannie_			

Concord, MA 01742-9133 Dated: 2/14/03

SEL DES.	COP (.	: OBPA/ HIODEA/ Indiage	03072					
PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 2825.2023-001	APPLICAT 10/066				
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICANT Todd R. Golub et al.					
February 14, 2003  (Use several sheets if necessary)			FILING DATE January 31, 2002	CONFIRMA 2026	TION NO.	GROUP 1642		
		E JC,		PATENT DOCUMENTS		~		
EXAM- INER INI- TIAL	0 %	DOCUMENT NU	MBER	ISSUE DATE / PUBLICATION DATE	TECH CENTER 1600200 ATTI			Ò
	\A	TEMT & TRADE			ECH	~ 6°	2003	
			FOREIG	N PATENT DOCUMENTS		CIVIER 16	· · · · · · · · · · · · · · · · · · ·	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	10/2900 11/2000	ATION ON
	AL	WO 02/02799	10 JAN 02	PCT				
-		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinent	Pages,	Etc.)		
	AW2			terogeneity in Medullob Tumor Biology," <i>J. Chi</i>			4:411-	417
-	AX2	Bertucci, F. et al., Gene expression profiling of primary breast carcinomas using arrays of candidate genes," Hum. Mol. Genet., 9:2981-2991 (2000).						
	AY2	Caskey, L. et al., "Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling," Histol. Histopathol., 15:971-981 (2000).						
	AZ2	Celis, J. et al., "Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics," FEBS Lett., 480:2-16 (2000).						
	AR3	Golub, T. et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring," Science, 286:531-537 (1999).						
	AS3	Huang, H. et al., "Gene Expression Profiling of Low-Grade Diffuse Astrocytes by cDNA Arrays," Cancer Res., 60:6868-6874 (2000).						
,	AT3	Liotta, L. and Petricoin, E., "Molecular Profiling of Human Cancer," Nat. Rev. Genet., 1:48-56 (2000).						
	AU3	Michiels, E. et al., "Genes differentially expressed in medulloblastoma and fetal brain," Physiol. Genomics, 1:83-91 (1999).						
	AV3	Ross, D. et al., Systematic variation in gene expression patterns in human cancer cell lines," Nat. Genet., $24:227-235$ (2000).						
	AW3	Scherf, U. et al., "A gene expression database for the molecular pharmacology of cancer," Nat. Genet., 236-244 (2000).						
	AX3	Watson, M. et al., "Gene Expression Profiling with Oligonucleotide Microarrays Distinguishes World Health Organization Grade of Oligodendrogliomas," Cancer Res., 61:1825-1829 (2001).						
EXAMIN	IER			DATE CONSIDERED				